Nucleofection-based screening of chimeric antigen receptor candidates in human natural killer cells
Open Access
- 3 April 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1557766
Abstract
Chimeric antigen receptor (CAR)-modified cell therapy products approved for clinical treatment of hematological malignancies have hitherto been based on T cells. NK cells represent a promising immune cell type that can be considered for CAR engineering due to their potential to be generated as off-the-shelf allogeneic cellular therapy. Viral transduction of NK cells with CARs has been fraught with challenges of long process time and poor CAR transduction efficiency. Here, we describe the development of an optimized protocol for electroporation-based delivery of CAR mRNA into NK cells expanded from human peripheral blood mononuclear cells in the presence of co-stimulating feeder cells. This enabled rapid assessment of the functional capacity of NK cells transiently expressing various CARs to kill liquid and solid tumor cells in vitro. Ultimately, we anticipate that such an approach will enable selection of CAR candidates for their subsequent clinical applicability and manufacturability.Keywords
This publication has 16 references indexed in Scilit:
- Current landscape of clinical use of ex vivo expanded natural killer cells for cancer therapyEinstein (São Paulo), 2024
- Natural killer cells in clinical development as non-engineered, engineered, and combination therapiesJournal of Hematology & Oncology, 2022
- Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potentialExperimental Hematology & Oncology, 2022
- Natural killer cells in antitumour adoptive cell immunotherapyNature Reviews Cancer, 2022
- A robust platform for expansion and genome editing of primary human natural killer cellsJournal of Experimental Medicine, 2021
- Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal antibody 2448Oncotarget, 2018
- Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancerJournal of Translational Medicine, 2015
- A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancerCancer Immunology, Immunotherapy, 2010
- The CD94/NKG2C-Expressing NK Cell Subset Is Augmented in Chronic Lymphocytic Leukemia Patients with Positive Human Cytomegalovirus SerostatusViral Immunology, 2009
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancerBlood, 2005